| Drug ID: | Drug190 |
|---|---|
| Drug Name: | Sulfasalazine |
| CID: | 5339 |
| DrugBank ID: | DB00795 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03414502, , NCT02714634, , NCT03254589, , NCT03739853, , NCT03847311, , NCT04720183, , NCT06060301, , NCT04725422, , NCT02451748, , NCT05580861, , NCT05664464, , NCT03561584, , NCT05703425, , NCT06360068, , NCT06134388, , NCT04205357, , NCT05445440, , NCT04610476, , NCT02374021, , NCT02466 |
| Molecular Formula: | C18H14N4O5S |
| Molecular Weight: | 398.4 g/mol |
| Isomeric SMILES: | C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O |
| Synonyms: | sulfasalazine; Salicylazosulfapyridine; Azulfidine; Sulphasalazine; Benzosulfa; Azopyrin; Sulfasalazina; Sulfasalazinum; Sulfasalazin; Azulfidine EN-tabs |
| Phase 0: | 1 |
| Phase 1: | 12 |
| Phase 2: | 13 |
| Phase 3: | 18 |
| Phase 4: | 20 |
| Description: | A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1325 | 5339 | Sulfasalazine | 9308 | CD83 | Homo sapiens (human) | None | |
| dt1326 | 5339 | Sulfasalazine | 240 | ALOX5 | Homo sapiens (human) | Arachidonate 5-lipoxygenase inhibitor | |
| dt1327 | 5339 | Sulfasalazine | 1719 | DHFR | Homo sapiens (human) | None | |
| dt1328 | 5339 | Sulfasalazine | 3091 | HIF1A | Homo sapiens (human) | None | |
| dt1329 | 5339 | Sulfasalazine | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt1330 | 5339 | Sulfasalazine | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt1331 | 5339 | Sulfasalazine | 5468 | PPARG | Homo sapiens (human) | None | |
| dt1332 | 5339 | Sulfasalazine | 38 | ACAT1 | Homo sapiens (human) | None | |
| dt1333 | 5339 | Sulfasalazine | 240 | ALOX5 | Homo sapiens (human) | Inhibitor | |
| dt1334 | 5339 | Sulfasalazine | 1544 | CYP1A2 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury
PMID: 28669550
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND AND AIMS: The chemokine CCL20 is over-produced in epithelium of Crohn's disease [CD] patients and contributes to recruiting immune cells …
Heme Oxygenase-1 Induction and Anti-inflammatory Actions of Atractylodes macroc…
PMID: 28651306
Year: 2017
Relationship Type:
Association
Score: 6.3
Erratum in Cell Rep. 2017 Jun 6;19(10 ):2174. Dysfunction in host immune responses and pathologic alterations in the gut microbiota, referred t…
[Adverse effects of sulfasalazine: discussion of mechanism and role of sulfonam…
PMID: 24356188
Year: 2013
Relationship Type:
Mechanism
Score: 6.1
Women with inherited bleeding disorders (IBD) require the input of a multidisciplinary team to improve outcomes of pregnancy. The role of the haemo…
Comparative evaluation of different doses of PPAR-γ agonist alone and in combin…
PMID: 24145089
Year: 2013
Relationship Type:
Mechanism
Score: 6.1
The pathophysiology of IBD is characterized by a complex interaction between genes and the environment. Genetic and environmental differences are at…
Green Tea Polyphenols and Sulfasalazine have Parallel Anti-Inflammatory Propert…
PMID: 23761791
Year: 2013
Relationship Type:
Treatment
Score: 6.1
Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (…
Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases
PMID: 21939920
Year: 2011
Relationship Type:
Treatment
Score: 6.1
Not found
Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TN…
PMID: 21374065
Year: 2011
Relationship Type:
Treatment
Score: 6.1
OBJECTIVE: Inflammatory bowel disease (IBD), which mainly refers to Crohn's disease and ulcerative colitis, is characterized by chronic inflammation…
Pleuropericardial effusion after 37 years of sulfasalazine therapy
PMID: 21228714
Year: 2012
Relationship Type:
Treatment
Score: 6.1
Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in …
PMID: 20833794
Year: 2010
Relationship Type:
Treatment
Score: 6.1
AMP-activated protein kinase (AMPK), a cellular energy sensor, has been reported to participate in modulating inflammatory responses, but its role i…
Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis
PMID: 19637363
Year: 2010
Relationship Type:
Association
Score: 6.1
Lipid peroxidation and antioxidant status in kidney and liver of rats treated w…
PMID: 19071188
Year: 2009
Relationship Type:
Treatment
Score: 6.1
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's dis…
Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells …
PMID: 16306769
Year: 2005
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Colitis in interleukin (IL)-10 mice is a CD4 T helper 1 (TH1)-mediated disease characterized by intermittent, transmural inflammation r…
Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and s…
PMID: 16298742
Year: 2005
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Phenantroline is a zinc-chelator that inhibits biological activities of matrix metalloproteinases (MMPs). Over-expression of MMPs can ac…
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfa…
PMID: 15735431
Year: 2005
Relationship Type:
Mechanism
Score: 6.1
Ly49A is a C-type lectin-like receptor on NK cells that recognizes MHC class I ligands, H-2D(d) and D(k). The engagement of Ly49A with the ligands i…
Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibi…
PMID: 11054378
Year: 2000
Relationship Type:
Treatment
Score: 6.1
The reason why 10% to 20% of all patients with primary sclerosing cholangitis (PSC) develop cholangiocarcinoma (CC) remains unknown. The aim of this…
Sperm size in patients with inflammatory bowel disease on sulfasalazine therapy
PMID: 6124462
Year: 1982
Relationship Type:
Treatment
Score: 6.1
Not found
Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontane…
PMID: 2872186
Year: 1986
Relationship Type:
Adverse Effect
Score: 6.1
Comment in Inflamm Bowel Dis. 2012 Nov;18(11):2199-200. OBJECTIVES: Patients with inflammatory bowel disease (IBD) often experience barriers to…
Sulfasalazine and renal tubular function: lack of an effect
PMID: 2858519
Year: 1985
Relationship Type:
Association
Score: 6.1
Not found
Inflammatory bowel disease induced by combined bacterial immunization and oral …
PMID: 1672517
Year: 1991
Relationship Type:
Association
Score: 6.1
Not found
Effects of sulfasalazine on selected lymphocyte subpopulations in vivo and in v…
PMID: 39716
Year: 1979
Relationship Type:
Association
Score: 6.1
Comment on J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):280-5.